11 completed, 1 recruiting, 1 terminated, 1 withdrawn. 14 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 11, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow AndroGel: new trials by email Literature Review of AndroGel trials Research Report on AndroGel
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc stereotactic ablative radiotherapy, Pluvicto, topical testosterone - Prostate Cancer | Phase 2 | Recruiting | VA Office of Research and Development | 60 | 2023-12-14 | 2025-12-31 |
| Gonadal Dysfunction in Male Long-term Survivors of Malignant Lymphoma; Vitality AndroGel - Hypogonadism | Phase 2 | Completed | Lars Møller Pedersen | 7 | 2021-04-01 | 2022-11-29 |
| ITT-5 Mechanisms of Spermatogenesis in Man Testosterone 1% Gel, Acyline, Dutasteride - Gonadotropin Deficiency | Phase 2 | Withdrawn | University of Washington | 2019-06-01 | 2019-12-18 | |
| Short-term Testosterone Replacement in Testicular Cancer Survivors Androgel (Testosterone gel), Placebo gel - Testicular Cancer | Phase 2 | Completed | University Medical Center Groningen | 32 | 2018-12-21 | 2024-07-30 |
| T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin Acyline, Testosterone 1.62% gel, Letrozole - Insulin Resistance, Type 2 Diabetes Mellitus | Phase 1 / Phase 2 | Completed | University of Washington | 53 | 2013-06-01 | 2018-05-08 |
| PROS-2 Dose Response Effects of Exogenous Testosterone on the Prostate placebo acyline, placebo gel, Testosterone 1% gel 1.25 g - Healthy | Phase 2 / Phase 3 | Completed | University of Washington | 62 | 2011-10-01 | 2017-10-05 |
| Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism Placebo, topical testosterone, Androxal - Secondary Hypogonadism | Phase 2 | Completed | Repros Therapeutics Inc. | 83 | 2011-01-01 | 2014-07-28 |
| ITT4 Intratesticular Hormonal Milieu in Man (ITT4) Acyline, Testosterone gel, ketoconazole 400 - Healthy Males | Phase 1 / Phase 2 | Completed | University of Washington | 46 | 2011-01-01 | 2014-03-31 |
| Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer AndroGel, placebo - Prostate Cancer | Phase 2 | Terminated | University of Chicago | 6 | 2007-07-01 | 2014-06-11 |
| Effects of Testosterone Gel on Carbohydrate and Lipid Metabolism In Elderly Obese Men Topical testosterone gel 10 g/day - Aging, Obesity | Phase 2 | Completed | University of Southern California | 22 | 2006-08-01 | 2019-08-26 |
| Effects of Testosterone Replacement on Pain Sensitivity and Pain Perception AndroGel, Placebo - Pain, Hypogonadism | Phase 2 | Completed | Boston University | 84 | 2006-04-01 | 2017-06-28 |
| TEAM: Testosterone Supplementation and Exercise in Elderly Men LowT, Resistance Training, Placebo - Healthy | Phase 2 | Completed | University of Colorado, Denver | 167 | 2005-01-01 | 2020-09-02 |
| Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer GnRh (Leuprolide), Testosterone Gel, Docetaxel - Prostate Cancer | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 102 | 2003-07-01 | 2023-11-07 |
| Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle GnRH, Ketoconazole, Bicalutamide - Prostate, Cancer | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 36 | 2001-07-01 | 2016-03-25 |
Hypogonadism (6) · Neoplasms (4) · Prostatic Neoplasms (3) · Insulin Resistance (2) · Obesity (2) · Diabetes Mellitus, Type 2 (1) · Lymphoma (1) · Lymphoma, Large B-Cell, Diffuse (1) · Metabolic Diseases (1) · Motor Activity (1) · Obesity, Abdominal (1) · Pain (1) · Sexuality (1) · Testicular Neoplasms (1)
University of Washington (4) · Memorial Sloan Kettering Cancer Center (2) · Boston University (1) · Lars Møller Pedersen (1) · Repros Therapeutics Inc. (1) · University Medical Center Groningen (1) · University of Chicago (1) · University of Colorado, Denver (1) · University of Southern California (1) · VA Office of Research and Development (1)
United States (12) · Denmark (1) · Netherlands (1)
Stephanie T Page, MD, PhD (2) · William J Bremner, MD, PhD (2) · Dana Rathkopf, MD, PhD (1) · Fred R Sattler, MD (1) · Howard Scher, MD (1) · Janine Nuver, MD, PhD (1) · Katya Rubinow, MD (1) · Larry Lipshultz, MD (1) · Mara Roth, MD (1) · Mara Y Roth, MD (1) · Nicholas George Nickols, MD PhD (1) · Robert S. Schwartz, MD (1) · Shehzad Basaria, MD (1) · Walter Stadler, MD (1)
PMID 22939385, PMID 23348398, PMID 25044085, PMID 25392748, PMID 25599449, PMID 27172434, PMID 27482750, PMID 27992261, PMID 28981994, PMID 29793828
I01CX002775 (1), R01AG019339 (1), R01AG037603 (1), U54HD012629 (1)